Get Premium to unlock powerful stock data

Bellevue Group AG Buys Sarepta Therapeutics Inc, Revolution Medicines Inc, Fate Therapeutics Inc, Sells Moderna Inc, Halozyme Therapeutics Inc, Charles River Laboratories International Inc

Author's Avatar
insider
Nov 12, 2021
Article's Main Image
Investment company Bellevue Group AG (Current Portfolio) buys Sarepta Therapeutics Inc, Revolution Medicines Inc, Fate Therapeutics Inc, Sage Therapeutics Inc, Amedisys Inc, sells Moderna Inc, Halozyme Therapeutics Inc, Charles River Laboratories International Inc, Glaukos Corp, Hill-Rom Holdings Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Bellevue Group AG. As of 2021Q3, Bellevue Group AG owns 220 stocks with a total value of $9.9 billion. These are the details of the buys and sells.

For the details of Bellevue Group AG's stock buys and sells, go to https://www.gurufocus.com/guru/bellevue+group+ag/current-portfolio/portfolio

These are the top 5 holdings of Bellevue Group AG
  1. Moderna Inc (MRNA) - 1,727,349 shares, 6.75% of the total portfolio. Shares reduced by 32.06%
  2. Vertex Pharmaceuticals Inc (VRTX) - 1,761,616 shares, 3.24% of the total portfolio. Shares added by 1.61%
  3. Ionis Pharmaceuticals Inc (IONS) - 9,347,926 shares, 3.18% of the total portfolio. Shares reduced by 5.86%
  4. argenx SE (ARGX) - 983,938 shares, 3.02% of the total portfolio. Shares added by 1.02%
  5. Neurocrine Biosciences Inc (NBIX) - 3,004,051 shares, 2.92% of the total portfolio. Shares reduced by 0.45%
New Purchase: Sarepta Therapeutics Inc (SRPT)

Bellevue Group AG initiated holding in Sarepta Therapeutics Inc. The purchase prices were between $65.97 and $92.48, with an estimated average price of $77.05. The stock is now traded at around $85.995000. The impact to a portfolio due to this purchase was 0.53%. The holding were 569,168 shares as of 2021-09-30.

New Purchase: Sight Sciences Inc (SGHT)

Bellevue Group AG initiated holding in Sight Sciences Inc. The purchase prices were between $22.34 and $39.1, with an estimated average price of $32.86. The stock is now traded at around $24.130600. The impact to a portfolio due to this purchase was 0.07%. The holding were 300,000 shares as of 2021-09-30.

New Purchase: PROCEPT BioRobotics Corp (PRCT)

Bellevue Group AG initiated holding in PROCEPT BioRobotics Corp. The purchase prices were between $35.91 and $41.94, with an estimated average price of $38.38. The stock is now traded at around $40.900000. The impact to a portfolio due to this purchase was 0.06%. The holding were 150,000 shares as of 2021-09-30.

New Purchase: Harmony Biosciences Holdings Inc (HRMY)

Bellevue Group AG initiated holding in Harmony Biosciences Holdings Inc. The purchase prices were between $25.68 and $38.61, with an estimated average price of $32.22. The stock is now traded at around $43.015000. The impact to a portfolio due to this purchase was 0.05%. The holding were 129,289 shares as of 2021-09-30.

New Purchase: Pfizer Inc (PFE)

Bellevue Group AG initiated holding in Pfizer Inc. The purchase prices were between $39.25 and $50.42, with an estimated average price of $44.27. The stock is now traded at around $49.675500. The impact to a portfolio due to this purchase was 0.04%. The holding were 99,600 shares as of 2021-09-30.

New Purchase: Bicycle Therapeutics PLC (BCYC)

Bellevue Group AG initiated holding in Bicycle Therapeutics PLC. The purchase prices were between $27.95 and $44.24, with an estimated average price of $35.01. The stock is now traded at around $57.330000. The impact to a portfolio due to this purchase was 0.03%. The holding were 65,700 shares as of 2021-09-30.

Added: Revolution Medicines Inc (RVMD)

Bellevue Group AG added to a holding in Revolution Medicines Inc by 86.48%. The purchase prices were between $23.95 and $33.41, with an estimated average price of $29.16. The stock is now traded at around $32.465000. The impact to a portfolio due to this purchase was 0.45%. The holding were 3,458,805 shares as of 2021-09-30.

Added: Sage Therapeutics Inc (SAGE)

Bellevue Group AG added to a holding in Sage Therapeutics Inc by 35.73%. The purchase prices were between $40.26 and $57.37, with an estimated average price of $46.02. The stock is now traded at around $42.150000. The impact to a portfolio due to this purchase was 0.38%. The holding were 3,209,004 shares as of 2021-09-30.

Added: Fate Therapeutics Inc (FATE)

Bellevue Group AG added to a holding in Fate Therapeutics Inc by 23.89%. The purchase prices were between $59.27 and $95.73, with an estimated average price of $78.58. The stock is now traded at around $55.810000. The impact to a portfolio due to this purchase was 0.38%. The holding were 3,238,036 shares as of 2021-09-30.

Added: Amedisys Inc (AMED)

Bellevue Group AG added to a holding in Amedisys Inc by 400.60%. The purchase prices were between $149.1 and $270.32, with an estimated average price of $208.37. The stock is now traded at around $181.990000. The impact to a portfolio due to this purchase was 0.37%. The holding were 302,798 shares as of 2021-09-30.

Added: Relay Therapeutics Inc (RLAY)

Bellevue Group AG added to a holding in Relay Therapeutics Inc by 42.22%. The purchase prices were between $29.75 and $37.99, with an estimated average price of $33.69. The stock is now traded at around $35.470000. The impact to a portfolio due to this purchase was 0.36%. The holding were 3,755,962 shares as of 2021-09-30.

Added: Jazz Pharmaceuticals PLC (JAZZ)

Bellevue Group AG added to a holding in Jazz Pharmaceuticals PLC by 41.21%. The purchase prices were between $128.64 and $184.79, with an estimated average price of $151.34. The stock is now traded at around $136.595000. The impact to a portfolio due to this purchase was 0.3%. The holding were 769,238 shares as of 2021-09-30.

Sold Out: Eargo Inc (EAR)

Bellevue Group AG sold out a holding in Eargo Inc. The sale prices were between $6.59 and $38.71, with an estimated average price of $26.78.

Sold Out: Intersect ENT Inc (XENT)

Bellevue Group AG sold out a holding in Intersect ENT Inc. The sale prices were between $18.11 and $28.01, with an estimated average price of $24.68.

Sold Out: Signify Health Inc (SGFY)

Bellevue Group AG sold out a holding in Signify Health Inc. The sale prices were between $17.87 and $30.5, with an estimated average price of $25.79.

Sold Out: (ALXN)

Bellevue Group AG sold out a holding in . The sale prices were between $179.45 and $186.61, with an estimated average price of $183.84.

Sold Out: Dicerna Pharmaceuticals Inc (DRNA)

Bellevue Group AG sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $19.68 and $39.99, with an estimated average price of $27.67.

Sold Out: ACADIA Pharmaceuticals Inc (ACAD)

Bellevue Group AG sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $15.78 and $24.77, with an estimated average price of $19.31.



Here is the complete portfolio of Bellevue Group AG. Also check out:

1. Bellevue Group AG's Undervalued Stocks
2. Bellevue Group AG's Top Growth Companies, and
3. Bellevue Group AG's High Yield stocks
4. Stocks that Bellevue Group AG keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus